Patient‐specific quality assurance (QA) is very important in radiotherapy, especially for patients with highly conformed treatment plans like VMAT plans. Traditional QA protocols for these plans are time‐consuming reducing considerably the time available for patient treatments. In this work, a new MC‐based secondary dose check software (SciMoCa) is evaluated and benchmarked against well‐established TPS (Monaco and Pinnacle³) by means of treatment plans and dose measurements.

中文翻译：

---

根据蒙特卡罗验证二次剂量检查工具和 VMAT 中的分析临床剂量计算算法

患者特定的质量保证 (QA) 在放射治疗中非常重要，特别是对于具有高度一致的治疗计划（如 VMAT 计划）的患者。这些计划的传统质量保证协议非常耗时，大大减少了患者治疗的时间。在这项工作中，通过治疗计划和剂量测量，对基于 MC 的新二级剂量检查软件 (SciMoCa) 进行了评估，并根据成熟的 TPS（Monaco 和 Pinnacle ^{3 ）进行了基准测试。}